Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: SOBI Says All Secondary Endpoints Favoured Pegcetacoplan Treatment

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    27/10/2024 14:28
    Oct 27 (Reuters) - Swedish Orphan Biovitrum AB (publ)
 SOBIV.ST :
    * PIVOTAL VALIANT RESULTS PRESENTED AT KIDNEY WEEK SHOW
PEGCETACOPLAN TREATMENT EFFECT IN PATIENTS WITH C3G / PRIMARY
IC-MPGN
    * SOBI - ALL SECONDARY ENDPOINTS FAVOURED PEGCETACOPLAN
TREATMENT
    * SOBI - SOBI TO SUBMIT MARKETING APPLICATION TO EMA IN 2025
    * SOBI - APELLIS TO SUBMIT SUPPLEMENTAL NEW DRUG APPLICATION
TO
FDA IN 2025

Source text:  ID:nPre1L4j8a 
Further company coverage:  SOBIV.ST 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news